XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.3
Note 7 - Equity
9 Months Ended
Sep. 30, 2025
Notes to Financial Statements  
Equity [Text Block]

NOTE 7 - EQUITY

 

The Company is authorized to issue 120,000 shares of Common Stock, $0.01 par value per share, of which 9,391 and 9,210 shares of Common Stock were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

 

Stock Split

 

On February 7, 2025, the Company effected a 2-for-1 stock split of its Common Stock and proportionately increased the number of authorized shares of Common Stock to 120,000. All share and per share information throughout this Quarterly Report on Form 10-Q has been retroactively adjusted to reflect the stock split as of the earliest period presented. The shares of Common Stock retain a par value of $0.01 per share. Accordingly, an amount equal to the par value of the additional shares issued in the stock split was reclassified from additional paid-in capital in excess of par value to Common Stock. 

 

Share Repurchase Program

 

On May 13, 2025, the Board approved the extension of the Company’s previously authorized share repurchase program, initially approved by the Board on August 16, 2019, as amended on September 23, 2019, November 6, 2019, February 1, 2021 and March 17, 2023 (“Share Repurchase Program”). Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000 of the Company's Common Stock over a period of 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management (the “2025 Share Repurchase Program”).

 

During the nine months ended September 30, 2025 and 2024, the Company did not repurchase any Common Stock under its share repurchase programs. As of September 30, 2025, the Company retained authorization to purchase $5,000 of Common Stock under the 2025 Share Repurchase Program.

 

Options

 

Information regarding options outstanding as of September 30, 2025 is as follows:

 

   

Number

of options

   

Weighted

average

exercise

price

   

Weighted

average

remaining life

(years)

 

Outstanding, December 31, 2024

    977     $ 3.74       3.5  

Issued

    8       18.73       4.9  

Exercised

    (181 )     3.78       -  

Forfeited

    -       -       -  

Outstanding, September 30, 2025

    804     $ 3.88       3.3  

 

Outstanding

   

Exercisable

 

Exercise price

per share

   

Total number

of options

   

Weighted

average

remaining life

(years)

   

Weighted

average

exercise price

   

Number of

vested options

   

Weighted

average

exercise price

 
                                               
$0.35

-

2.38

     

542

     

3.4

   

$

0.77      

542

   

$

0.77  
$5.77

-

18.73

     

262

     

3.2

   

$

10.33      

167

   

$

9.94  
           

804

     

3.3

   

$

3.88

     

709

   

$

2.93

 

 

The closing stock price for the Company’s Common Stock on September 30, 2025 was $19.89, resulting in an intrinsic value of outstanding options of $12,875.

 

In September 2025, the Company granted stock options to purchase 8 shares of Common Stock to employees. The stock options are exercisable at $18.73 per share. The stock options expire in five years and vest (i) one fourth immediately on the date of grant, and (ii) in three equal annual installments thereafter. The total fair value of these options at grant date was approximately $70, which was determined using a Black-Scholes option pricing model with the following assumptions: stock price of $18.73 per share, expected term of 5 years, volatility of 50%, dividend rate of 0%, and risk-free interest rate of 3.24%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior. The expected volatility is based upon historical volatility of the Company’s Common Stock. The expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

During the three-month periods ended September 30, 2025 and 2024, the Company recognized stock-based compensation of $126 and $141, respectively, related to stock options. During the nine-month periods ended September 30, 2025 and 2024, the Company recognized stock-based compensation of $332 and $344, respectively, related to stock options. As of September 30, 2025 there is $181 of unamortized stock-based compensation related to stock options.